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Protein foldingTo prevent the accumulation of misfolded and aggregated proteins, the cell has developed a complex net-
work of cellular quality control (QC) systems to recognize misfolded proteins and facilitate their refolding
or degradation. The cell faces numerous obstacles when performing quality control on transmembrane pro-
teins. Transmembrane proteins have domains on both sides of a membrane and QC systems in distinct com-
partments must coordinate to monitor the folding status of the protein. Additionally, transmembrane
domains can have very complex organization and QC systems must be able to monitor the assembly of trans-
membrane domains in the membrane. In this review, we will discuss the QC systems involved in repair and
degradation of misfolded transmembrane proteins. Also, we will elaborate on the factors that recognize fold-
ing defects of transmembrane domains and what happens when misfolded transmembrane proteins escape
QC and aggregate. This article is part of a Special Issue entitled: Protein Folding in Membranes.
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Accumulation of misfolded proteins in a cell can lead to disruption
of global protein homeostasis. To prevent the accumulation of toxic
protein species, the cell has developed a variety of cellular quality
control (QC) systems to recognize misfolded proteins and facilitate
their refolding or degradation [1–5]. The cell contains a variety ofn Folding in Membranes.
ental Biology, 527 Taylor Hall,
27514, USA.
r).
l rights reserved.factors, notably molecular chaperones, which aid in the folding of
proteins and degradation of terminally misfolded proteins [6]. Failure
of protein QC systems to manage protein loads can result in protein
aggregation and formation of toxic protein species, the molecular
basis for a number of diseases.
Transmembrane proteins present interesting problems for QC sys-
tems. First, transmembrane proteins have domains on both sides of a
membrane and QC systems in distinct compartments must coordinate
to monitor the folding status of the protein. Second, transmembrane
domains can have very complex organization and QC systems must
be able to monitor the assembly of transmembrane domains. Several
destabilizing mutations in transmembrane domains of proteins are
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mentosa, hypercholesterolemia, diabetes insipidus, and hypogonado-
tropic hypogonadism [7–12]. Misfolded transmembrane domains will
expose hydrophilic residues in the hydrophobic environment of the
membrane that would normally be involved in hydrogen bonding to
the hydrophobic environment of the membrane (Fig. 1). Here, we
will discuss QC systems used for misfolded polytopic transmembrane
proteins, how the cell recognizes folding defects in transmembrane
domains, and what happens when transmembrane proteins
aggregate.
2. Folding/misfolding of transmembrane proteins
There are two distinct types of transmembrane spanning domains
in proteins: β-barrel and α-helix. α-helix transmembrane spans are
common and are inserted into the ER membrane co-translationally
via the Sec61 translocon complex[13]. The translocon, which binds
to ribosomes [14], consists of a complex composed of the Sec61α, β,
and γ subunits and translocating chain-associating membrane pro-
tein (TRAM) [15,16]. Sec61 forms a hydrophobic tunnel in the mem-
brane that creates a chemical environment in which translating
transmembrane polypeptides can insert into the membrane and
achieve proper structure [17–19]. The Sec61 tunnel can accommodate
two helices at one time and facilitate interhelical bonds between
them [20]. However, many proteins have a complex network of
more than two transmembrane spans and the translocon must have
a mechanism to prevent the co-translational aggregation of such pro-
teins (discussed in Section 2.2.1). In contrast, the less common β-
barrel transmembrane domains, which are found exclusively on the
outer-membrane of bacteria, chloroplast, and mitochondria, consist
of a large coiled β-sheet that form a pore in the membrane [21]. Fold-
ing of the highly ordered β-barrel domain occurs in the inner mem-
brane space in a process mediated by soluble chaperones such as
Skp [22]. Once the proper folding is achieved, β-barrels are post-
translationally inserted into the membrane via an energetically spon-
taneous process [23].
2.1. QC of polytopic membrane proteins in the ER
Transmembrane proteins can have a wide range of topologies,
ranging from proteins consisting of a single transmembrane α-helix
to proteins with more than 20 transmembrane helices and large sol-
uble domains on both sides of the membrane [13]. To deal with this
variety, multiple ER-membrane associated E3 ubiquitin ligases have
been identiﬁed that target different types of terminally misfolded
membrane proteins for degradation [24] (Fig. 2). The ubiquitin ligase
HRD1 forms a functional QC complex with many proteins including
SEL1L, OS-9, the Derlin proteins, and E2 ubiquitin-conjugating en-
zymes [25–27]. The HRD1 complex has been implicated in the recog-
nition of misfolding in the transmembrane spans and the ER luminalFig. 1. Quality control of a protein with a misfolded transmembrane domain. A misfolded tr
lices will display polar residues on the surface of the helix (indicated with stars) that can be
from aggregating, potentially allowing for the refolding. Terminally misfolded proteins will
gate and be degraded by autophagy.domains of polytopic membrane proteins. SEL1L and OS-9 are be-
lieved to serve as recognition factors for misfolded ER luminal do-
mains [24]. Another ubiquitin ligase, GP78, is homologous to HRD1
and is involved in similar QC processes [28]. The RMA1 E3 ubiquitin
ligase functions in a complex with Derlin-1, the E2 ubiquitin-
conjugating enzyme UBE2J1, and DNAJB12 [29,30]. DNAJB12 is a
transmembrane HSP40 chaperone with a cytosolic J-domain that co-
operates with cytosolic Hsp70 to recognize misfolding in cytosolic do-
mains of polytopic membrane proteins, allowing for RMA1 mediated
ubiquitination. Little is known about an additional mammalian QC
ubiquitin ligase, TEB4, but the yeast homolog, Doa10, is involved in
QC of polytopic membrane proteins with cytosolic domains [31]. Re-
cently it was shown that a diverse group of 24 transmembrane ubi-
quitin ligases localize to the ER membrane, suggesting that there
may be many uncharacterized transmembrane ubiquitin ligases in-
volved in the QC of membrane proteins in the ER [32]. Additionally,
a host of cytosolic QC factors and ubiquitin ligase aid in the QC of
polytopic membrane proteins with cytosolic domains [2,33].2.1.1. Cystic ﬁbrosis transmembrane conductance regulator (CFTR) as a
model transmembrane QC substrate
The ion-channel cystic ﬁbrosis transmembrane conductance regu-
lator (CFTR) is a prominent model substrate used in the investigation
of QC of membrane proteins. CFTR is a polytopic membrane protein
containing twelve transmembrane spans, a cytoplasmic regulatory-
domain, and two large cytoplasmic nucleotide-binding domains
(NBD1/2) [34]. Mutations in CFTR are the molecular basis for cystic ﬁ-
brosis (CF), a common recessive disorder [35,36]. While over one
thousand different CF-causing mutations in CFTR have been discov-
ered, 69% of afﬂicted people worldwide carry at least one copy of
the ΔF508 mutation and as such ΔF508 CFTR is the by far the most
studied CFTR mutant [37]. Phenylalanine-508 of CFTR is part of
NBD1 and deletion of this residue creates a folding defect in the cyto-
plasmic domains of CFTR [38]. While, ΔF508 CFTR does appear to re-
tain some function, virtually none of the protein reaches the cell
surface. Instead, a network of quality control factors retains ΔF508
CFTR in the endoplasmic reticulum where it is targeted for proteaso-
mal degradation.
Due to the cytoplasmic folding defect of ΔF508 CFTR, a series of
checkpoints involving both ER and cytoplasmic factors are used in
QC. Cytosolic Hsc70 interacts with HSP40, the U-box ubiquitin ligase
CHIP, and the E2 UbcH5 to form an E3 complex that recognizes and
ubiquitinates misfolded ΔF508 CFTR [33,39,40]. Additionally, mis-
folded ΔF508 CFTR is independently recognized by the ER membrane
associated Hsp40 DNAJB12 [29,30]. DNAJB12 recruits the RMA1 com-
plex to ubiquitinate misfolded CFTR [41]. CFTR that has been ubiqui-
tinated by RMA1 and/or CHIP is extracted from the membrane into
the cytoplasm via the p97 AAA+ATPase and degraded by the
proteasome.ansmembrane protein may have improperly aligned transmembrane helices. These he-
recognized by membrane chaperones. Chaperones will prevent the misfolded protein
be degraded by the proteasome. Proteins that escape chaperone recognition will aggre-
Fig. 2. ER-membrane localized complexes that target misfolded membrane proteins for degradation. Misfolded membrane proteins are recognized by various ER factors, such as
molecular chaperones, and directed towards ER membrane associated E3 ubiquitin-ligases. The three main mammalian ligases identiﬁed are HRD1, RMA1 and TEB4. Each ligase
is part of a complex with an E2 ubiquitin-conjugating enzyme and other proteins that are involved in recognition. HRD1 substrates tend to have folding defects in luminal and trans-
membrane domains. RMA1 substrates are polytopic membrane proteins with large cytoplasmic domains. Substrate proteins are ubiquitinated by the respective ligase, extracted
into the cytoplasm via the p97 AAA+ATPase, and degraded by the proteasome.
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area of intense investigation, it is not known how the cell would rec-
ognize CFTR mutants that cause misfolding in the transmembrane
spans. Of the 20 most common disease-causing CFTR mutations,
three of them are mutations to transmembrane spans (G85E, R347P,
and R334W). However, very little is known about the quality control
of these CFTR mutants. G85E CFTR is degraded before it can exit the
ER and none of the protein reaches the cell surface [42,43]. Degrada-
tion of G85E is dependent on the membrane protein Derlin-1 and it is
suggested that Derlin-1 is serving as a recognition factor for mis-
folded G85E CFTR [42]. However, much research into the QC mecha-
nisms of misfolded CFTR and other disease-related transmembrane
proteins remains.
2.2. Transmembrane domain chaperones
The key ﬁrst step in a QC pathway is the recognition of a misfolded
protein. Misfolded soluble proteins typically display hydrophobic
patches on the surface of the protein that would normally be buried
in the core. These hydrophobic patches are recognized by molecular
chaperones, allowing the misfolded protein to enter a QC pathway
[44]. However, less is known about the molecular factors that aid in
recognition of misfolded transmembrane domains and the basis for
recognition in the lipid bilayer. The proper folding of α-helix based
transmembrane domains is achieved through a series of inter- and
intra-helical hydrogen bonds and salt bridges [45]. A “misfolded”
transmembrane domain will have misaligned helices and may expose
polar residues that would normally be involved in hydrogen bonding
to the hydrophobic environment of the membrane (Fig. 1). Aplausible model is that exposed polar residues could be recognized
by molecular chaperones with active transmembrane domains that
monitor the folding status of client transmembrane domains. Addi-
tionally, transmembrane proteins that are unable to properly oligo-
merize or form complexes with binding partner will also expose
polar/charged residues in the membrane that can be recognized as
misfolded by transmembrane domain chaperones. While these
models of recognition are plausible, no experimental evidence direct-
ly conﬁrms them. In extreme cases of misfolding, transmembrane he-
lices may not properly insert into the membrane. The uninserted
transmembrane helix will be generally hydrophobic and exposed in
an aqueous environment providing a basis for recognition by cytosol-
ic chaperones. As an example, an unstable helix in CFTR is often not
properly inserted into the membrane and contributes to improper
biogenesis of CFTR [46].
While no transmembrane domain chaperones have been exten-
sively characterized, several proteins have been identiﬁed that could
function as transmembrane domain chaperones in various QC
pathways.
2.2.1. The Translocon and TRAM
The Sec61 translocon contains a hollow hydrophobic tunnel in the
membrane that creates a chemical environment in which translating
membrane polypeptides can insert into the membrane and achieve
proper folding [17–19]. The translocon tunnel can accommodate
two helices at one time and facilitate interhelical bonds between
them [20]. However, some proteins have a complex network of
more than twenty transmembrane helices and the translocon channel
would be unable to facilitate the organization of such proteins. It has
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tein (TRAM), an essential component of the translocon complex
[15,16], could act as a transmembrane domain chaperone [47,48].
Chemical crosslinking experiments show that TRAM interacts with
translocated helices containing charged residues in translating poly-
peptides [49,50]. TRAM contains four relatively hydrophilic trans-
membrane helices that could be sites for recognition of exposed
charges in client transmembrane helices [48]. A general model for
TRAM as a chaperone would be that it binds exposed polar/charged
residues in already inserted transmembrane helices of translating
polypeptides, preventing aggregation until all the protein has been
completely synthesized so that proper folding can be achieved.
2.2.2. Escherichia coli YidC
In E. coli, the protein YidC has been highly implicated as a key
player in membrane protein biogenesis and shown to be an interactor
of the E. coli translocon [51–53]. Notably, YidC is required for the
proper folding of the lactose permease LacY [52]. As LacY contains a
very complex 12-membrane spanning domain, with no signiﬁcant cy-
tosolic or periplasmic domains, this suggests that YidC is a chaperone
that helps organize complex transmembrane domains. A distantly re-
lated mammalian homolog of YidC (Oxa1L) localizes to the mitochon-
dria and interacts with mitochondrial ribosomes, suggesting that
Oxa1L could have a similar function to YidC in the mitochondria
[54]. However, no proteins with any signiﬁcant homology to YidC
are found outside of the mitochondria and thus there are no YidC-
like proteins that could act as a transmembrane domain chaperone
in the ER, where the bulk of membrane protein synthesis takes place.
2.2.3. Yeast Shr3p
Shr3p is an 4 transmembrane spanning protein in yeast that rec-
ognizes, prevents aggregation of, and facilitates refolding of trans-
membrane domains of general amino-acid permease 1 (Gap1)
[55,56]. Gap1 contains 12 transmembrane helices with no signiﬁcant
extracellular or cytoplasmic domains suggesting that Shr3p acts as a
chaperone to fold and organize transmembrane domains. There are
no obvious mammalian homologs of Shr3p.
2.2.4. HRD1
The ER membrane associated ubiquitin-ligase HRD1 is involved in
the degradation of numerous proteins with transmembrane folding
defects [24,57]. Mutations to the transmembrane domain of HRD1
prevent proteins with misfolded transmembrane domains, but not
ER luminal domains, from being degraded [58]. Additional in vitro
studies suggest that the transmembrane domain of HRD1 directly rec-
ognizes misfolded membrane proteins. A reasonable model is that the
transmembrane domain of HRD1 binds misfolded transmembrane
domains of client proteins, bringing the client protein into a complex
with the cytosolic RING-ﬁnger domain, allowing for ubiquitination
and proteasomal degradation.
2.2.5. Derlin-1
It has suggested that the known QC factor Derlin-1 can act as a
transmembrane domain chaperones [30]. Derlin-1 forms complexes
with membrane spanning domain 1 (MSD1) of CFTR, which lacks
any cytoplasmic structure, and Derlin-1 promotes ER retention and
degradation of CFTR [41,42]. Degradation of G85E CFTR, a transmem-
brane domain mutant, is dependent on Derlin-1 and it is suggested
that Derlin-1 can serve as a recognition factor for misfolded G85E
CFTR [42]. Derlin-1 interacts with the ER transmembrane ubiquitin li-
gases RMA1 and HRD1 [24,41]. An interesting model is that Derlin-1
provides an additional level of recognition of substrates for these ubi-
quitin ligases, in a manner similar to the transmembrane domain of
HRD1. While Derlin-1 is predicted to have 4 transmembrane spans,
recent evidence suggest that it actually has 6 transmembrane spans
which contain a number of polar and charged residues [59].2.2.6. BAP29/BAP31
BCR-associated proteins 29/31 (BAP29/BAP31) are ubiquitously
expressed transmembrane proteins that form a high molecular
weight complex that likely functions as transmembrane domain
chaperones involved in the QC of transmembrane proteins in the
ER. BAP29/BAP31 is involved in the recognition and ER retention of
membrane-bound immunoglobulins (mIgs) with unstable trans-
membrane domains [60]. However, BAP31 does not interact with
and retain an mIg that contains very hydrophobic and stable trans-
membrane domains [60]. BAP29 and BAP31 have multiple exposed
polar and charged residues in their transmembrane spans. It is pro-
posed that these polar/charged residues can interact with exposed
hydrophilic sequences in unstable transmembrane spans of mIgs,
providing a molecular basis for recognition and retention [60]. Simi-
larly, BAP31 has been implicated in the ER retention of several other
transmembrane proteins with known unstable transmembrane do-
mains, including CFTR, cellubrevin, and cytochrome P450 2 C2
[61,62]. The fact that BAP29/BAP31 can regulate the ER retention of
proteins with diverse functions and a wide range of topologies sug-
gest that it may be a general ER transmembrane domain chaperone,
rather than a regulator of a speciﬁc biological process. An analogous
high molecular weight complex found in the mitochondria, consisting
of prohibitin and BAP37, is involved in the stabilization of membrane
proteins in the mitochondria [63].3. Aggregation and autophagy of transmembrane proteins
Misfolded proteins that escape recognition by molecular chaper-
ones are prone to aggregation [64]. Aggregates can be toxic to the
cell and need to be degraded [65,66]. Aggregates cannot be degraded
by the proteasome as they are physically too large to enter the narrow
proteasomal barrel [67]. While protein aggregates can be disaggre-
gated by certain molecular chaperones, this does not appear to be
the primary mechanism of aggregate clearance in mammalian cells
[68]. Instead, aggregates are often degraded by macroautophagy
[69]. Macroautophagy (simply referred to as autophagy) is a process
in which parts of the cell, such as aggregated or damaged organelles,
are packaged into double-membrane autophagosome and sent to the
lysosome for degradation [70]. Unlike the proteasome, the lysosome
is easily capable of degrading large protein aggregates (Fig. 3). Re-
cently, there has been a signiﬁcant amount of investigation into
how the cell recognizes and targets protein aggregates for autophagic
degradation.
When the proteasome is inhibited various soluble and integral
membrane proteins, including CFTR, are sent to the aggresome, an in-
clusion body formed at the microtubule organizing center [71]. Some
proteins targeted to the aggresome are degraded by autophagy, and it
has been suggested that the aggresome may be a sequestration com-
partment for proteins prior to autophagic degradation [72,73]. Addi-
tionally, yeast with impaired proteasomal degradation accumulate
CFTR in an aggresome-like compartment, and eventually degrade it
via autophagy [74]. However, in mammalian cells, CFTR that accumu-
lates during proteasome inhibition does not appear to be degraded by
autophagy suggesting that the aggresome is a holding compartment
for misfolded/aggregated membrane proteins [75].
Very few examples of membrane proteins being degraded by
autophagy are found in the literature. A mutant form of dysferlin, a
single transmembrane spanning protein with a large (>200 amino
acids) cytoplasmic domain, has been shown to be partitioned be-
tween the proteasome and the lysosome [76]. Similarly, mutant
mouse olfactory receptors have been shown to accumulate in the
presence of lysosome inhibitors, suggesting that they are degraded
by autophagy [77]. While it is clear that membrane proteins can be
selected for autophagy, the mechanism for how membrane proteins
are selected for and degraded by autophagy is entirely unknown.
Fig. 3. Model for the partitioning of misfolded membrane proteins between autophagy and proteasomal degradation. Native proteins are prone to unfolding. Unfolded membrane
proteins with cytosolic domains can be recognized by molecular chaperones (i.e. HSP70), preventing aggregation. The unfolded protein will be refolded or targeted for proteasomal
degradation by ubiquitin ligases (i.e. CHIP) via K48-linked poly ubiquitin chains. Additionally, Misfolded/unfolded proteins are prone to aggregation. Aggregated proteins can be
resolubilized by disaggregates or degraded by autophagy. Aggregates may be conjugated with K63-linked polyubiquitin chains. The ubiquitin binding protein p62 will bind K63-
linked polyubiquitin chains and facilitate the packaging of aggregates into autophagosomes. Autophagosomes will fuse with the lysosome and aggregates will be degraded. Addi-
tionally, it is possible that membrane protein aggregates could be degraded by microautophagy, an autophagosome independent form of autophagy.
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sol are ubiquitin positive and that inactivation of autophagy causes a
buildup of ubiquitinated aggregates [64,69,78]. Speciﬁcally, it has
been suggested that certain types of polyubiquitin chains will target
proteins to different fates (Fig. 3) [79]. Soluble proteins being tar-
geted for autophagy will have K63-linked polyubiquitin chains,
while those being targeted for the proteasome will have primarily
K48-linked polyubiquitin chains. Several ubiquitin binding proteins
that have a high afﬁnity for K63-linked polyubiquitin chains, such as
p62, NBR1, and HDAC6, have been implicated in selection of sub-
strates for autophagy [80–82]. This led to the model that protein ag-
gregates are conjugated with K63-linked polyubiquitin chains and
selected for autophagy by these ubiquitin binding proteins [78,79].
This model is controversial as it has been shown that in autophagy
deﬁcient mice, all types of polyubiquitin linkages accumulate and
not just K63-linkages [83]. This seems to suggest that ubiquitination
of aggregated protein is merely an indirect consequence. However,
as there is tight crosstalk between proteasomal and autophagic deg-
radation pathways [84,85] it is unclear exactly what the expected re-
sults would be in these experiments.A disease-causing mutant of the soluble protein α1-antitrypsin is
known to be degraded by autophagy in a ubiquitin independent man-
ner. When overexpressed, the Z-variant of α1-antitrypsin (ATZ) will
aggregate in the ER lumen and sections of the ER containing these ag-
gregates are selectively packaged into autophagosomes [86,87].
While the exact mechanism for autophagic degradation of ATZ is
not clear, it is possible that aggregated transmembrane proteins in
the ER could be degraded by the same mechanism as luminal ATZ
aggregates.
4. Concluding remarks
Many major questions remain about how the cell deals with mis-
folded membrane proteins. First, what QC factors are responsible for
the recognition of misfolded transmembrane spans? As discussed in
Section 2.2, several proteins have been implicated as transmembrane
domain chaperones, however the mechanism by which most of these
proteins act and the diversity of their substrates remains poorly un-
derstood. Also, how are aggregated membrane proteins selected for
autophagy? Is this via ubiquitin dependant autophagy, or perhaps a
1113S.A. Houck, D.M. Cyr / Biochimica et Biophysica Acta 1818 (2012) 1108–1114process similar to autophagy of ATZ aggregates in the ER lumen? As
only several examples of transmembrane proteins that are degraded
by autophagy have been described, the ability to answer this question
will depend on the identiﬁcation and characterization of more trans-
membrane proteins that are degraded by autophagy. Answers to
these questions will give insight into the fundamental biological
mechanisms that are the basis for a diverse set of diseases.References
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